Glenmark Pharmaceuticals Limited - Neraca (Quarterly)

Glenmark Pharmaceuticals Limited
IN ˙ NSEI ˙ INE935A01035
₹ 2,053.50 ↑62.90 (3.16%)
2025-09-05
BAHAGING PRESYO
Talaan ng Balanse (Quarterly)

Neraca Glenmark Pharmaceuticals Limited menunjukkan saldo akun perusahaan pada titik waktu tertentu. Data Neraca meliputi Aset, Aset Lancar, Aset Tetap, Properti, Pabrik dan Peralatan (PPE), Persediaan, Aset Tak Berwujud, Kewajiban, Kewajiban Lancar, Utang, Kewajiban Sewa Modal, Saham Biasa, Laba Ditahan, Saham Perbendaharaan, dan Ekuitas Pemegang Saham.

Semua angka adalah kelipatan 1,000,000.00 kecuali unit per saham.

2020
09-30
2021
03-31
2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
Cash 8,881 11,381 14,296 14,105 12,400 11,592 11,240 16,583 18,202 16,757
Change (%) 28.15 25.62 -1.34 -12.09 -6.52 -3.04 47.53 9.77 -7.94
Assets Current 69,803 73,596 80,732 82,823 89,592 107,255 112,669 74,281 90,335 92,955
Change (%) 5.43 9.70 2.59 8.17 19.71 5.05 -34.07 21.61 2.90
Assets 150,915 156,036 166,135 170,833 180,308 193,717 200,064 143,586 152,353 160,496
Change (%) 3.39 6.47 2.83 5.55 7.44 3.28 -28.23 6.11 5.34
Liabilities 85,966 85,393 76,135 76,452 80,916 95,324 102,707 65,111 67,898 72,005
Change (%) -0.67 -10.84 0.42 5.84 17.81 7.75 -36.61 4.28 6.05
Equity 64,949 70,643 89,999 94,381 99,392 98,393 97,357 78,475 84,455 88,491
Change (%) 8.77 27.40 4.87 5.31 -1.01 -1.05 -19.39 7.62 4.78
Liabilities And Stock Equity 150,915 156,036 166,135 170,833 180,308 193,717 200,064 143,586 152,353 160,496
Change (%) 3.39 6.47 2.83 5.55 7.44 3.28 -28.23 6.11 5.34

Source: Capital IQ

Other Listings
IN:532296
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista